U.S. market Closed. Opens in 4 hours 29 minutes

TRDA | Entrada Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 12.71 - 13.15
52 Week Range 11.35 - 21.79
Beta 1.06
Implied Volatility 106.29%
IV Rank -0.28%
Day's Volume 92,850
Average Volume 123,723
Shares Outstanding 37,419,975
Market Cap 488,704,874
Sector Healthcare
Industry Biotechnology
IPO Date 2021-10-29
Valuation
Profitability
Growth
Health
P/E Ratio 9.07
Forward P/E Ratio N/A
EPS 1.44
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 177
Country USA
Website TRDA
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
*Chart delayed
Analyzing fundamentals for TRDA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is poor, Growth is desperately bad and Health is strong. For more detailed analysis please see TRDA Fundamentals page.

Watching at TRDA technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on TRDA Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙